It has been incorporated into the ‘Expert Consensus on Multigene Testing for Adjuvant Therapy of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer’ in China and recommended in the ‘Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Breast Cancer 2022’ for guiding precise postoperative radiotherapy in N1 patients. Here, NR4A1 is linked to breast carcinoma.